Leading commercial and transactional healthcare executive Shawn Cline Tomasello joins Mesoblast board

Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that Shawn Cline Tomasello (pictured) has joined its Board of Directors. With more than 30 years’ experience in the pharmaceutical and biotech industries, Ms Tomasello brings substantial commercial and transactional experience to the Mesoblast board.

Since 2015, Ms Tomasello has been Chief Commercial Officer at leading immuno-oncology cell therapy company Kite Pharma, where she played a pivotal role in the company’s acquisition in 2017 by Gilead Sciences for $11.9 billion. Prior to this she served as Chief Commercial Officer at Pharmacyclics, Inc., which was acquired in 2015 by AbbVie, Inc. for $21 billion. Ms Tomasello previously was President of the Americas, Hematology and Oncology at Celgene Corporation where she managed over $4 billion in product revenues, and was instrumental in various global expansion and acquisition strategies. She has also held senior positions at Genentech, Pfizer Laboratories, Miles Pharmaceuticals and Procter & Gamble. Ms Tomasello currently serves on the Board of Directors of Centrexion Therapeutics, Oxford BioTherapeutics and Diplomat Rx. 

Commenting on her appointment, Ms Tomasello said, “I have been extremely impressed by Mesoblast’s technology and the rigor with which the company has moved its programs towards commercialization. Mesoblast’s cellular medicines have the potential to make a substantial impact on the treatment of life-threatening conditions in a way not possible with traditional approaches. I look forward to making an important contribution to Mesoblast’s commercial and strategic objectives.”

Mesoblast Chief Executive Dr Silviu Itescu stated: “Shawn’s substantial commercial experience will be invaluable to the Mesoblast product launch team as we transition to a commercial-stage company.  As important, Shawn’s unparalleled transactional experience will greatly strengthen our ability to execute on our strategic objectives.”

Ignite Partners advised Mesoblast on the appointment of Ms Tomasello.